Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWatkins, L.en
dc.contributor.authorHutchinson, M.en
dc.contributor.authorJohnson, K.en
dc.identifier.citationExperimental Neurology, 2012; 234(2):351-353en
dc.description.abstractLandry et al. provide a 2-part study. Part 1 reports the failure of propentofylline to show reduced pain in patients with post-herpetic neuralgia. Part 2 reports cell culture results for macrophages and microglia. Comments regarding each are provided below. Such significant concepts to the field of translational validity of glial cell modulation and related pharmacotherapy as reported in Landry et al. warrant higher standards of study design and data presentation than their paper affords.en
dc.description.statementofresponsibilityLinda R. Watkins, Mark R. Hutchinson, Kirk W. Johnsonen
dc.publisherAcademic Press Inc Elsevier Scienceen
dc.rights© 2012 Elsevier Inc. All rights reserveden
dc.subjectFETAL; Neuralgia; Postherpetic - drug therapy; Macrophages - drug effects; BRAIN; Microglia - drug effectsen
dc.titleCommentary on Landry et al.: "Propentofylline, a CNS glial modulator, does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages"en
dc.typeJournal articleen
pubs.library.collectionPhysiology publicationsen
dc.identifier.orcidHutchinson, M. [0000-0003-2154-5950]en
Appears in Collections:Physiology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.